InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,433.74
(
0.23%
)
US TECH 100
19,114.80
(
0.24%
)
Dow Jones
38,647.10
(
-0.17%
)
Brent Oil
82.03
(
0.07%
)
Bitcoin
67,155.24
(
0.60%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119832
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 7457

Wednesday, 04/30/2008 2:55:10 PM

Wednesday, April 30, 2008 2:55:10 PM

Post# of 19309
NovoSeven update:

1Q08 sales were $301M (DKK 1,440M), +10% YoY in local currencies and +2% YoY in DKK. However, sales declined by 5% in DKK relative to 4Q07.

In short, NovoSeven has reached blockbuster status but continued growth is problematic due to the colossal cost per dose. (Lowering production cost is, of course, the impetus for GTC’s rFVIIa program with LFB.)

NVO has scrapped NovoSeven in favor of NN1731 (a short-acting FVIIa analogue) in the CABG indication after a phase-2 trial failed to show a benefit vs placebo.

http://www.novonordisk.com/images/investors/reports/interim_reports/2008/PR080430_Q1%202008_UK.pdf

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up